Sionna Therapeutics, Inc. - Common Stock (SION)

Sionna Therapeutics (NASDAQ:SION) said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis. The company also reported

This risk is weighing on the stock.

This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.

This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.

This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.

This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions.

Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.

AI Mobility provider Webus International, steel industry veteran Luda Technology, Chinese ad services provider LZ Technology, and Singapore-based med-tech Basel Medical all made their public debuts this week.

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a modest opening, just slightly higher than its initial pricing.